Safety and efficacy evaluation of ambrisentan in pulmonary hypertension

Author： Vizza Carmine Dario   Fedele Francesco   Pezzuto Beatrice   Rubin Lewis J.  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.11, Iss.6, 2012-11, pp. : 1003-1011

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ambrisentan: a guide to its use in pulmonary arterial hypertension

By Behr Jürgen  

Drugs & Therapy Perspectives, Vol. 25, Iss. 7, 2009-07 ,pp. : 1-5

Adis International

Access to resources Recommend Favorite

Ambrisentan: a guide to its use in pulmonary arterial hypertension classified as WHO functional class II or III

By Behr Jürgen  

Drugs & Therapy Perspectives, Vol. 27, Iss. 1, 2011-01 ,pp. : 1-8

Adis International

Access to resources Recommend Favorite

Pharmacokinetic evaluation of ambrisentan

By Buckley Mitchell S   Wicks Laura M   Staib Robin L   Kirejczyk Anna K   Varker Andrew S   Gibson Jamie J   Feldman Jeremy P  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 3, 2011-03 ,pp. : 371-380

Informa Healthcare

Access to resources Recommend Favorite

One-Year Evaluation of the Safety and Efficacy of Ipratropium Bromide HFA and CFC Inhalation Aerosols in Patients with Chronic Obstructive Pulmonary Disease

By Brazinsky S.A.  

Clinical Drug Investigation, Vol. 23, Iss. 3, 2003-01 ,pp. : 181-191

Adis International

Access to resources Recommend Favorite

Ambrisentan

By Frampton James E.  

American Journal of Cardiovascular Drugs, Vol. 11, Iss. 4, 2011-08 ,pp. : 215-226

Adis International

Access to resources Recommend Favorite